Fredun Pharmaceuticals gains on launching new platform 'PAWTALKS' for pet, animal healthcare
Fredun Pharmaceuticals is currently trading at Rs. 1495.00, up by 6.80 points or 0.46% from its previous closing of Rs. 1488.20 on the BSE.
The scrip opened at Rs. 1524.50 and has touched a high and low of Rs. 1524.50 and Rs. 1484.00 respectively. So far 1217 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1600.00 on 17-Aug-2026 and a 52 week low of Rs. 390.18 on 22-Sep-2025.
Last one week high and low of the scrip stood at Rs. 1529.00 and Rs. 1433.00 respectively. The current market cap of the company is Rs. 2466.32 crore.
The promoters holding in the company stood at 44.57%, while Institutions and Non-Institutions held 4.00% and 51.43% respectively.
Fredun Pharmaceuticals has launched PAWTALKS, India's trusted platform for conversations on pet and animal healthcare. PAWTALKS has been launched as a dedicated platform that brings together veterinary experts, researchers, pet parents, animal welfare advocates, and industry leaders to share knowledge, foster meaningful conversations, and help build a more informed pet care ecosystem.
This platform is not merely a podcast on pets. It has been envisioned as a knowledge-first platform designed to make all relevant information related to pet & pet healthcare accessible to everyone from first time pet parents and experienced caregivers to aspiring veterinarians and professionals across the animal healthcare ecosystem. PAWTALKS will cover a wide range of subjects, including preventive healthcare, diagnostics, nutrition, behaviour, emerging veterinary technologies, animal welfare, and inspiring stories from the veterinary community.
Launching initially on YouTube and Instagram, PAWTALKS will feature full-length conversations, short educational videos, myth-versus-fact segments, expert explanation, behind-the-scenes content, and interactive community engagement initiatives.
